Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This article describes the clinical history of a woman aged 75 with a pseudolymphoma syndrome that was probably a consequence of the use of carbamazepine. This syndrome is characterised by lymphadenopathy, fever and a generalised rash. These signs can easily be confused with the existence of a true malignant T-cell lymphoma or Hodgkin's disease. Chemotherapy may be given to these patients if this adverse reaction, which mimicks a true malignant lymphoma, is not recognised. After withdrawal of the drug the symptoms disappear mostly in a few days.
 ...
PMID:[Pseudolymphoma syndrome following use of carbamazepine]. 832 12

We report a case where acute varicella infection, chickenpox, mimics the findings of recurrent Hodgkin disease on F-18 FDG PET/CT. A 28-year-old man with a history of Hodgkin disease in remission had fatigue, pyrexia, and a raised ESR. His F-18 FDG PET/CT, performed to exclude lymphoma recurrence, demonstrated FDG-avid lymphadenopathy and increased FDG uptake in his spleen. A day later he developed the generalized rash of acute varicella infection. This was managed with valacyclovir. Repeat F-18 FDG PET/CT done 1 month later showed no evidence of FDG-avid disease. In this patient the stimulation of an immune response by the acute viral infection mimics recurrent lymphoma.
 ...
PMID:Acute varicella infection mimics recurrent Hodgkin's disease on F-18 FDG PET/CT. 1788 70

Brentuximab vedotin is a monoclonal antibody that targets the CD30 antigen. It is indicated for the treatment of Hodgkin lymphoma. Hypersensitivity reactions have occurred during infusions of brentuximab vedotin, ranging from mild to severe. We report a case of a 46-year-old male with stage IV nodular sclerosis Hodgkin lymphoma who developed a hypersensitivity reaction to brentuximab vedotin. He experienced a generalized rash, facial swelling, and mild airway obstruction. In order to continue treatment with brentuximab vedotin, we implemented a desensitization protocol. He was premedicated and a 12-step process was performed in which brentuximab vedotin was titrated over three hours. The protocol was successful, allowing the patient to receive subsequent infusions without hypersensitivity reactions.
 ...
PMID:Desensitization of Brentuximab Vedotin in a Patient with Hodgkin Lymphoma. 3023 42